No abstract available
Keywords:
Anti-programmed death 1; Anti-programmed death ligand 1; Emergent adverse event; Eosinophilia; Immune-related adverse event.
Publication types
-
Letter
-
Observational Study
MeSH terms
-
Administration, Intravenous
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
B7-H1 Antigen / antagonists & inhibitors
-
B7-H1 Antigen / immunology
-
Eosinophilia / chemically induced*
-
Eosinophilia / epidemiology
-
Eosinophilia / immunology
-
Female
-
Humans
-
Male
-
Melanoma / drug therapy*
-
Melanoma / epidemiology
-
Melanoma / pathology
-
Middle Aged
-
Nivolumab
-
Pharmacovigilance
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / immunology
-
Retrospective Studies
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / epidemiology
-
Skin Neoplasms / pathology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
B7-H1 Antigen
-
CD274 protein, human
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
durvalumab
-
Nivolumab
-
pembrolizumab